Kornimate/medical-research-clean huggingface dataset:
diagnostic evaluation of out-of-hospital high-sensitivity troponin i in patients presenting chest pain

Conditions: Chest Pain

Summary: conducting an analysis of the clinical performance of high-sensitivity cardiac troponin i, tested in the out-of-hospital setting, for ruling out cardiac origin in acute onset chest pain. acute onset chest pain is a complex symptom to narrow down in the out-of-hospital setting. this is due to the difficulty of obtaining pertinent information over the phone, and the absence of validated dispatch scores or criteria. in france, the current standard of care relies on the rapid dispatch of emergency medical response teams along with a physician in patients presenting symptoms evocative of coronary artery disease or myocardial infarction. typical anginal pain includes retrosternal pressure pain radiating to the jaw, neck, or left arm. diagnostic work-up includes anamnesis, physical examination, routine blood work, and ecg. in the absence of signification st-segment modifications, the gold standard relies on trending serum troponin t and i in the hospital setting . this study aims to analyze the clinical performance of high-sensitivity cardiac troponin i assays (hs-ctni) in the out-of-hospital setting using a point-of-care device ; atellica vtli (siemens healthineers)


Eligibility criteria:
inclusion criteria: * over 18 years of age * presenting with evocative acute onset chest pain exclusion criteria: * ecg modifications with st segment elevations * patients for whom anginal origin was excluded in the out-of-hospital setting * medical evaluation in a delay inferior to 20 minutes * patients without medical insurance * pregnant or lactating women * patients under reinforced guardianship, minors, patients in hospice care

Keywords: high-sensitivity cardiac troponin i troponin i hs
incidence of acute lung injury in children

Conditions: Acute Lung Injury; Children

Summary: acute lung injury in children is a syndrome of rapid onset of acute respiratory failure and require admission into intensive care units (icu) for advanced life support. there are almost no information on epidemiology of acute lung injury. published studies do not have information for an entire year and none of them have evaluated the degree of oxygenation failure under standard ventilator settings. the investigators will perform a 1-year prospective audit of all patients admitted with acute lung injury in a network of pediatric icus in spain.

we will evaluate oxygenation under standard ventilator settings (fio2 0.5 and 1 on peep 5 or 10 cmh2o) in pediatric acute respiratory distress syndrome. outcome measures will include: overall icu mortality, number of patients meeting ards criteria at 24 hours, and stratification of patients depending on pao2/fio2 ratio at 24 h of meeting acute respiratory distress syndrome criteria.

Eligibility criteria:
inclusion criteria: * acute onset of respiratory failure * age 1 month to 18 years old * bilateral pulmonary infiltrates on chest x-ray * absence of left ventricular failure, pao2/fio2\>300 mmhg exclusion criteria: * none

Keywords: acute lung injury incidence lung damage pao2/fio2 ratio
therapeutic patient education and cancer pain

Conditions: Cancer

Summary: describe the expectations of therapeutic education for patients in management of cancer pain.


Eligibility criteria:
inclusion criteria: * patient with cancer diagnosed for at least one month * patient with pain from the tumor or its treatment * patients with a life expectancy ≥ 6 months * health condition compatible with the requirements of the program (who performance scale \< or= 2) * age over 18 years * patient able to understand, speak and read french * absence of cognitive impairment exclusion criteria: * primary cancer of the central nervous system or brain metastases * disorders of the documented higher functions * evolutionary psychiatric pathology * drug user * abusive alcohol consumption than the who recommendations (or 3 glasses of wine per day) * refusal to participate
comparation between needles for eus-guided sampling of solid pancreatic lesions

Conditions: Pancreatic Neoplasms

Summary: this is a randomized study in order to compare the diagnostic yield (primary outcome) of eus-guided sampling of pancreatic solid lesions obtained with the 25-gauge franseen and the 25-gauge standard needle in patients undergoing eus-guided sampling of pancreatic solid masses without rose. secondary outcomes are the number of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry and the adverse event rate.

this is a randomized trial conducted at a unique center. the aim of this study is to compare the diagnostic yield (primary outcome) of eus-guided sampling of pancreatic solid lesions obtained with the 25-gauge franseen and the 25-gauge standard needle in patients undergoing eus-guided sampling of pancreatic solid masses without rose. secondary outcomes are the number of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry and the adverse event rate. patients with a suspected solid pancreatic lesion larger than 15 mm, identified by ct or mri and referred to eus-guided sampling will be eligible for inclusion. patients will be excluded in case of cystic lesion, or the lesion was not detected in eus, or if the coagulation parameters are abnormal (inr\> 2, platelet count \< 50,000). the pancreatic mass will be puncture, for expert endoscopist, firstly with a needle according to randomization, followed by another one. will be make a touch print with the specimen obtained with the needles and, subsequently, all the specimen will be put in formaldehyde solution for cell-block analysis. diagnostic yield of cell block will be defined as enough histologic tissue core containing pancreatic parenchyma or tumor with dysplastic cells enough for the correct tissue diagnosis. in the presence of malignant tissue in core specimens, it will be calculated the proportion of the area positive for malignancy compared to the total area of the core and then the each needle yield will be defined.

Eligibility criteria:
inclusion criteria: - solid pancreatic lesion larger than 15 mm exclusion criteria: * pancreatic cystic lesion * lesion not detected in eus * abnormal coagulation parameters (inr\> 2, platelet count \< 50,000)

Keywords: accuracy pancreatic cancer endoscopic ultrasound-guided
qi: patient satisfaction with facial appearance, scar outcome and quality of life after skin cancer surgery

Conditions: Skin Cancer

Summary: the purpose of this study is to evaluate patient satisfaction and quality of life as it relates to skin cancer surgery. this research study involves taking a one-time survey online.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age at the time of surgery. * had a diagnosis of a cutaneous malignancy on the face * cutaneous malignancy includes, but is not limited to basal cell carcinoma, squamous cell carcinoma, and melanoma * the face is defined as location in the following areas: forehead, temple, eyebrow, eyelids, cheek, nose, lips, chin, and ears. * able to speak and read english * msk only cross sectional study: radiation therapy patients ≥ 18 years of age who have received rt for skin cancer exclusion criteria: * unable to speak and read english

Keywords: quality of life survey 18-168
weaning protocol for high flow nasal cannula oxygen therapy

Conditions: High Flow Nasal Cannula; Respiratory Insufficiency

Summary: high flow nasal cannula oxygen therapy has been widely used in critically ill patients. despite effectiveness of high flow nasal cannula as a treatment, optimal methods to withdrawal high flow nasal cannula after recovery from preexisting conditions has not been investigated to date. in this study, we will evaluate the efficacy and safety of three different weaning methods in patients with high flow nasal cannula oxygen therapy.

comparison of three weaning strategies: flow reduction first versus fraction of inspired oxygen (fio2) first versus simultaneous reduction

Eligibility criteria:
inclusion criteria: * the patients applying high flow nasal cannula and satisfying the following weaning criteria. 1. patient who has recovered from the underlying condition 2. no signs of respiratory distress like agitation, diaphoresis or anxiety 3. arterial ph ≥ 7.35, spo2 \> 90% on fio2 ≤ 0.5 4. respiratory rate ≤ 25/min, heart rate ≤120/min, systolic blood pressure ≥ 90mmhg exclusion criteria: * severe hypercapnia (ph \<7.25) * respiratory arrest requiring tracheal intubation * cardiac arrest, acute coronary syndrome or life threatening arrhythmias * failure of more than two organs * recent trauma or burns of the neck and face * non- cooperation * pregnancy * refusal of treatment

Keywords: high flow nasal cannula weaning adult
to evaluate the clinical efficacy of probiotics in patients with the breast cancer

Conditions: Breast Cancer

Summary: chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. this study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.

in 2020, the incidence rate of women's breast cancer in taiwan was up to 82.1% . the death rate increased to 16%; in 2021, the ranking rose to no.3, and the death rate grew up to 24.6%. in the decades, breast cancer gradually becomes the dominant malignant women's cancer in taiwan. besides the lumpectomy, chemotherapy is one of the dominant and important treatments for breast cancer. beyond the effects of chemotherapy, several side effects rise up. the most common chemotherapy are anthracyclin drugs (doxorubicin and epirubicin) and taxane (docetaxel and paclitaxel ). there are common side effects including neutropenia, hair loss, vomiting, diarrhea, stomatitis, mucositis, peripheral neuropathy, dermatitis, nephrotoxicity, and hepatotoxicity. currently, most treatments for chemotherapy-induced side effects are symptomatic treatment, but there is no good solution to prevent it.

Eligibility criteria:
inclusion criteria: * stage i-iii breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery) * bmi \> 18 kg/m\^2 * age between 20 and 80 years old * patients judged by physicians to participate in this trial and who are willing exclusion criteria: * pregnant or lactating female patients * patients with bariatric surgery, gastrointestinal resections, crohn's disease, celiac disease * bmi \< 18 kg/m\^2 * patient who have severe allergy to soybeans or peanuts * those who are under 20 years old or over 80 years old

Keywords: probiotics chemotherapy side-effects breast carcinoma gut microbiot lactobacillus reuteri lactobacillus plantarum lactobacillus paracasei
studying the analgesic mechanism of the "cough-trick"

Conditions: Pain; Acute Pain; Venipuncture

Summary: the aim of the trial is to study the possible mechanism of the pain reducing effect of ct at peripheral venipuncture


Eligibility criteria:
inclusion criteria: 1. male volunteers aged 20-40 years, height 165-190 cm. 2. physical status i according to american society of anesthesiologists (asa) classification. 3. straight run of the vein on the dorsum of the non-dominant hand at least 4 cm long and 3 mm thick 4. no analgesics, anticoagulants and/or antiplatelet agents, sedatives or alcohol exclusion criteria: 1. history of peripheral neuropathy 2. abnormal skin conditions (infection, scars, psoriasis, eczema) 3. unsuccessful venipuncture 4. inflamed site of vp within 1 week after vp

Keywords: acute pain pain on venipuncture "cough-trick" distraction
effectiveness of tofacitinib in systemic sclerosis

Conditions: Efficacy of Tofacitinib in the Systemic Sclerosis

Summary: the goal of this clinical trial is to compare efficacy of tofacitinib with cyclophosphamide in skin thickening in early diffuse cutaneous systemic sclerosis .

compare tofacitinib 5mg twice daily with cyclophosphamide 500mg/m2/month in early diffuse cutaneous systemic sclerosis

Eligibility criteria:
* inclusion criteria: 1. diagnosis of ssc, as classified using the 2013 american college of rheumatology 2. dcssc as defined by 2001 leroy and medsge 3. disease duration ≤ 60 months (defined as time from the first non-raynaud phenomenon manifestation) 4. mrss units ≥ 10 and ≤ 45 at screening. 5. oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including the baseline visit. 6. calcium channel blocker and pdfe-5 inhibitors for raynaud's and digital ulcers are permitted to use as oral monotherapy 7. age ≥ 18 years and ≤ 70 years 8. ability to provide informed consent. exclusion criteria: subjects with any of the following characteristics/conditions will not be included in the study: 1. any infection at screening . 2. oral corticosteroids \>10 mg/day of prednisone or equivalent. 3. pulmonary disease with fvc ≤ 35% of predicted. 4. subjects at risk for tuberculosis (tb).specifically excluded from this study with a history of active tb within the last 3 years and current clinical, radiographic, or laboratory evidence of active tb.j 5. latent tb at or within 30 days of screening. 6. positive for hepatitis b surface antigen at or within 30 days of screening. 7. positive for hepatitis c antigen at or within 30 days of screening. 8. current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease. 9. history of diverticulitis or chronic, ulcerative lower gi disease such as crohns disease, ulcerative colitis, or other symptomatic, lower gi conditions that might predispose a patient to perforations. 10. pregnant or breastfeeding female subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after discontinuation of study drug. 11. history of any malignancy in the last 5 years with the exception of adequately treated or excised basal cell or squamous cell or cervical cancer in situ. 12. history of ssc renal crisis within the 6 months prior to baseline. 13. history of live/attenuated vaccine ≤ 6 weeks prior to baseline 14. any of the following lab results at screening: * hemoglobin \<9 g/dl or hematocrit \<30% * white blood cell count \<3.0 x 109/l; * absolute neutrophil count \<1.2 x 109/l; * platelet count \<100 x 109/l; * absolute lymphocyte count \<0.75 x 109/l. * alt or ast \> 3 × the upper limit of normal (uln) of normal at screening or any * total bilirubin \> uln at screening. * estimated glomerular filtration rate \[gfr\] \<40ml/min/1.73 m2
advanced understanding of staphylococcus aureus infections in europe - surgical site infections

Conditions: Staphylococcus Aureus; Surgical Wound Infection

Summary: aspire-ssi is a prospective, observational, multicentre cohort study among adult surgical patients, which aims to determine the incidence of healthcare-associated s. aureus infections, particularly s. aureus surgical site infections (ssis), across europe and to assess the most important risk factors for this type of infection.

the primary objective of aspire-ssi is to determine the incidence of s. aureus infections, particularly s. aureus ssis, in various adult surgical patient populations, and to identify the patient-related, pathogen-related, and contextual risk factors for the development of s. aureus ssi. using this information, a ssi prediction tool will be derived for future clinical trials and public health interventions aimed at ssi prevention. furthermore, immunologic features protective against s. aureus ssi will also be assessed. the knowledge obtained by this study will enable identification of the surgical patients most at risk of developing s. aureus infections, particularly s. aureus ssi, and who would probably benefit most from new interventions given prophylactically and specifically to prevent s. aureus infections.

Eligibility criteria:
inclusion criteria: * the subject is 18 years of age or older. * the subject is undergoing 1 of the protocol-defined surgical procedures. the surgical procedure is planned or unplanned. * the subject has been screened for s. aureus colonization from three body regions: nose, throat, and perineum within 30 days prior to surgery, and based on the preoperative s. aureus colonization status of the subject, the subject qualifies for enrolment in the study cohort. * written informed consent has been obtained prior to enrollment in the study cohort. exclusion criteria: * parallel participation in any experimental study of an anti-staphylococcus preventive intervention. * an active diagnosis of a ssi as the reason for surgery. * not able to comply with study procedures and follow-up based on investigator judgment.

Keywords: epidemiology staphylococcus aureus prospective observational surgical site or wound infection
ivf failure and pregnancy loss on couples' psychological stress

Conditions: Fertilization in Vitro; Pregnancy Loss; Psychological Stress; Post-traumatic Stress

Summary: the goal of this observational study is to learn about the purpose of this study was to compare the psychological differences between couples after ivf transplant failure and ivf pregnancy loss, including the differences in anxiety, depression, stress and post-traumatic stress between women and their spouses. the main question it aims to answer is: what are the psychological effects of ivf implantation failure and ivf pregnancy loss on women and the psychological differences between couples? participants already taking ivf as part of their regular medical care will answer online survey questions about their joint pain for 1 years.

the goal of this observational study is to learn about the purpose of this study was to compare the psychological differences between couples after ivf transplant failure and ivf pregnancy loss, including the differences in anxiety, depression, and stress between women and their spouses. some couples will experience symptoms of post-traumatic stress reaction (pts), and there are also large differences. the differences between couples discussed in this study also pay attention to male spouses. guidance and education for male spouses can reduce cognitive differences between couples and generate understanding and empathy, which is conducive to promoting the stability of family relations and intimate relationships. 1. does the number of ivf implant failures have a differential effect on anxiety, depression and fertility stress in women and their partners? 2. does pregnancy loss after ivf transplantation have a differential effect on anxiety, depression, fertility stress and post-traumatic stress responses in women and their partners?

Eligibility criteria:
inclusion criteria: 1. couples who have undergone ivf at our center and have completed at least 1 embryo transfer. 2. female age 20-45 years, male age 22-45 years. exclusion criteria: 1. couples with contraindications to pregnancy. 2. couples who undergo donor ivf. 3. infertility women caused by organic lesions. 4. couples with previous mental disorders.

Keywords: ivf failure ivf pregnancy loss psychological stress post-traumatic stress anxiety and depression
exploration of clonal hematopoiesis of indeterminate potential in non-ischemic heart failure with reduced ejection fraction

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: clonal hematopoiesis of indeterminate potential (chip) refers to a phenomenon in which blood cells with somatic mutation circulate in the peripheral blood due to abnormal proliferation and differentiation of mutant hematopoietic cells. chip is considered one of the aging phenomena, and the mutant blood cells increased by chip cause chronic inflammation, thereby increasing the occurrence of atherosclerotic cardiovascular disease. therefore, chip is known to be closely related to poor prognosis of ischemic heart failure. meanwhile, chronic inflammation may be involved in the development of non-ischemic myocardial disease, which is one of the major causes of heart failure. this study will identify chip and perform nlrp3 inflammasome assay in 100 non-ischemic heart failure patients and evaluate the relationship between chip and inflammation, imaging markers of heart failure, left ventricle reverse remodeling after guideline-directed medical treatment, and prognosis of heart failure with reduced ejection fraction.


Eligibility criteria:
inclusion criteria: 1. as an adult over the age of 19 2. a history of left ventricular ejection fraction less than 40% on imaging tests within 3 years (hfref diagnosis), 3. have a cardiac mri taken within 3 months of being diagnosed with hfref, 4. a person who was diagnosed with non-ischemic heart failure by performing coronary artery imaging (angiography, ct) at the time of diagnosis of hfref exclusion criteria: 1. patients with confirmed ischemic cardiomyopathy (when stenosis of 75% or more of major coronary arteries is confirmed on coronary artery imaging or ischemic cardiomyopathy findings such as transmural late gadolinium enhancement on cardiac mri) 2. history of solid cancer diagnosis and chemotherapy (drugs, radiation) 3. history of blood cancer
forcerepair - a wound exudate investigation

Conditions: Venous Leg Ulcer; Wound Healing; Non-healing Wound; Cytokines

Summary: the observational longitudinal study will collect wound exudate from twenty patients with venous leg ulcers. wound exudate samples are collected using twenty-four-hour collection with polyurethane foam, bandages and the novaswab method. each patient is seen four times where wound exudate and the bacteria microbiome are sampled and wound size is monitored with advanced planimetric tools.

this dual centre longitudinal observational study will run from january 2024 to january 2025. the investigation will include twenty patients over four weeks including four study visits. sampling of wound exudate can take place on every visit and will be made with the polyurethane discs, the novaswab technique and waste bandages. the wound bacteria microbiome is sampled with routine bacterial swabs. tape strips will be used to assess perilesional skin and control sites of normal skin and will primarily measure skin inflammation parameters. clinical pictures are taken and analysed using advanced planimetric tools. patients enrolled receive standard wound care; allowing all kinds of dressing. however when consenting to twenty-four-hour-collection patients will not be allowed to wear active bandages or receive antibiotic treatment for that period. compression, wound dressings, and use of topical and oral antibiotics will be registered. for the storage of samples, a research biobank is used, and leftover material will be stored in a biobank for future research.

Eligibility criteria:
inclusion criteria: * adults fulfilling all inclusion criteria * age \>18 years * venous leg ulcer diagnosis and classic characteristics (localisation, varicose veins, brown-orange hyperpigmentation, leg oedema, stasis dermatitis, atrophie blanche or lipodermatosclerosis) verified by a wound expert (if in doubt venous doppler will be used for verification) * wound area equal to or above 1 cm2 (measured with a ruler length x width) * patient can understand danish * patient can comply with protocol * patient is fully informed about the study and has given informed consent exclusion criteria: * venous leg ulcer with communication to bone * known or suspected cancer in the wound * allergies towards products used in the study, e.g. polyurethane foam and tegaderm * dementia * judgement by the investigator that the patient is not suited for study participation

Keywords: venous leg ulcer varicose ulcer cytokines wound exudate wound healing wound inflammation wound microbiome